PREDICT Ltd.
The Nuclear Medicine & Life Sciences Strategic Consultancy
Predict Ltd provides strategic and transactional consultancy to clients seeking to create value in the Nuclear Medicine / Imaging / Radiotherapeutics space.
Nuclear Medicine & Life Sciences
Strategic Consultancy
What We Believe In
Value Based Pricing
Customer & Patient Focused
Dependability & Security of Supply
Innovation & Disruption
Building Teams & Growth
360 Degree Understanding
Previous Assignments
Advising the Australian Government, through ANSTO – appointed to develop an independent business case that expertly considers the options available to provide a secure medium to long term sustainable future of nuclear medicine supply to patients in Australia.
Advising a leading Private Equity Company regarding the possible sale of a global Nuclear Medicine Company.
Strategic Advisor to Urenco Limited regarding Medical Isotopes
Strategic Advisor to SHINE Medical
Help to CPDC (Centre for Probe Development and Commercialisation) in forming a new spin out – NuGeneris
Strategic Advice for Cardinal Health, Nuclear & Precision Health Solutions
Who Are Predict Ltd.
Martyn Coombs
CEO
Martyn Coombs is a recognised industry leader in Nuclear Medicine.
In 2012-16, as President, he led Jubilant DraxImage through a period of rapid organic growth – tripling revenue in four years. He built a strong team, advanced the development pipeline towards approval, and helped reset a more value-based industry. More recently, as President BWXT Medical, he
repositioned the company to the centre of the rapidly emerging therapeutic field.
Martyn has also held senior executive roles at Amersham (now GE Healthcare) and Nihon-Medi Physics, where he was the number two Executive. He has served as Strategic Advisor to SHINE Medical, raised funds for ImaginAb, and advised the Australian Government on fostering a sustainable long-term supply of nuclear medicine products.
Martyn has lived and worked in the US, Japan, Canada and Europe.
Martyn holds a degree in Mathematics and an MBA with distinction from Warwick Business School.
Tamara Mills is a recognised leader in accelerating market success and value realization of innovative therapeutics, diagnostics and imaging technologies.
Tamara has a strong track record in portfolio asset management across both the nuclear medicine sector and broader medical technology sector, previously directing the portfolio of pipeline assets from Jubilant Draximage (JDI). As Director of JDI’s cardiovascular business Tamara successfully built the Cardiology business from the ground up leading RUBY-FILL® , a complex drug/device system, through to regulatory approval and commercialization.
Tamara has held several board positions in the life sciences sector, most recently holding the position of Chair of the Health Policy, Regulatory and Reimbursement committee for the North American Radiopharmaceutical Industry organization CORAR in addition to holding a key leadership role for the Medical Imaging Technology Alliance. Tamara is currently co-chair of Ausbiotech, is the authorised investment manager for CEA venture capital funds and sits on the investment advisory board of one of the most prominent venture capital funds in Australia.
Tamara Mills has an MBA, Masters in Health Economics, a Degree in Nuclear Medicine and a qualification in New Ventures Leadership from the Massachusetts Institute of Technology.
Tamara Mills
Principal
Ian McLellan
Associate: Market Analyst
An experienced commercial manager in high technology businesses, Ian consistently contributes to significant sales growth and market development in the medical diagnostics and radiopharmaceutical sectors.
He has held senior strategic marketing roles in nuclear medicine and medical imaging at Amersham (now GE Healthcare) and was responsible for in-licencing two ground-breaking nuclear imaging compounds. As a senior Business Development Manager in the UK National Health Service (NHS), he has first-hand experience of Health Provider procurement and contracting.
Recent consultancy projects include the development of a European market entry strategy for a major radioisotope supplier. As Commercial Director at Feedback plc, he was instrumental in the market development of Artificial Intelligence for enhanced PET/CT imaging, and a novel software product for remote access of medical images by clinicians.
With an academic background in physics providing an excellent grounding in the fields of radioisotopes, magnetic resonance, nuclear medicine, Ian applies his technical and commercial skills over a wide range of newly developing technology.
Ian qualified as an accredited Business Coach for the UK Government Business Growth Service, and has led Innovation Masterclasses for Medilink West Midlands.
CONTACT
Predict Ltd provides strategic and transactional consultancy to clients seeking to create value in the Nuclear Medicine / Imaging / Radiotherapeutics space.
To contact Predict Ltd please send us your details in the form below:
To avoid spam emails, we use Captcha to ensure emails cannot originate from ‘bots‘ so please answer the sum above before you press Submit.